非对比磁共振用于心脏淀粉样变性的诊断
本研究在868例疑似系统性淀粉样变性患者中评估原生T1诊断心脏淀粉样变性的价值。原生T1在心脏轻链型和转甲状腺素蛋白型淀粉样变性中均显著升高,总体曲线下面积为0.93;原生T1<1,036 ms对心脏淀粉样变性阴性预测值为98%,>1,164 ms阳性预测值为98%。作者提出用这两个 cut-off 值排除或确认心脏淀粉样变性,仅对中间概率(原生T1 1,036–1,164 ms)患者使用对比剂。
要点
- 原生T1<1,036 ms对心脏淀粉样变性阴性预测值98%,>1,164 ms阳性预测值98%。
- 原生T1诊断心脏淀粉样变性总体AUC为0.93。
- 中间概率(原生T1 1,036–1,164 ms)患者占58%,此部分需对比剂。
核心结论
- 原生心肌T1可在大部分疑似系统性淀粉样变性患者中无需钆对比剂即诊断心脏淀粉样变性,作者提出适用于疑似淀粉样变性患者的非对比CMR诊断算法。
研究设计与样本
- 前瞻性队列研究,纳入2015年至2017年间868例疑似心脏淀粉样变性患者,均接受含晚期钆增强、T1 mapping和一系列临床检查的心脏磁共振。
关键影像表现/征象
- 心脏轻链型淀粉样变性和心脏转甲状腺素蛋白型淀粉样变性中原生T1均显著升高。
诊断标准与关键数值
- 原生T1<1,036 ms对心脏淀粉样变性阴性预测值为98%。
- 原生T1>1,164 ms对心脏淀粉样变性阳性预测值为98%。
- 原生T1诊断心脏淀粉样变性总体曲线下面积为0.93。
- 最终诊断:心脏轻链型淀粉样变性222例,心脏转甲状腺素蛋白型淀粉样变性214例,无心脏受累427例。
临床应用与阅片要点
- 作者提出用原生T1<1,036 ms排除心脏淀粉样变性、>1,164 ms确认心脏淀粉样变性。
- 作者提出仅对中间概率(原生T1 1,036–1,164 ms)患者使用对比剂,该组占本队列58%。
- 作者提出一种适用于疑似淀粉样变性患者的非对比CMR诊断算法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study aimed to assess the diagnostic use of native T1 to detect cardiac amyloidosis (CA) in a large prospective cohort of patients referred for suspected systemic amyloidosis.
BACKGROUND: CA is a progressive and fatal underdiagnosed cause of heart failure. Cardiovascular magnetic resonance (CMR) has emerged as an extremely useful test for the non-invasive diagnosis of CA, but administration of contrast is still required to make a diagnosis.
METHODS: In this study, 868 patients with suspected CA referred between 2015 and 2017 underwent CMR with late gadolinium enhancement (LGE), T1 mapping, and an array of clinical investigations.
RESULTS: The final diagnosis was cardiac light-chain (AL) amyloidosis in 222, cardiac transthyretin (ATTR) amyloidosis in 214, and no cardiac involvement in 427 cases. T1 was significantly elevated in both types of CA and this was associated with high diagnostic accuracy in the overall population (area under the curve, 0.93). A native T1 <1,036 ms was associated with 98% negative predictive value for CA whereas a native T1 >1,164 ms was associated with 98% positive predictive value for CA. We propose the use of these cut-offs to exclude or confirm CA and to restrict the administration of contrast only to patients with intermediate probability (native T1 between 1,036 and 1,164 ms), 58% of patients in this population.
CONCLUSIONS: Native myocardial T1 enables diagnosis of CA to be made without need for gadolinium contrast in a large proportion of patients with suspected systemic amyloidosis. We propose a diagnostic algorithm for non-contrast CMR applicable to patients with suspected amyloidosis.
引用
- Baggiano A, Boldrini M, Martinez-Naharro A, et al. Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2019. PMID: 31202744. doi:10.1016/j.jcmg.2019.03.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。